Skip to main content

Fangzhou Secures 2nd National Science Foundation Project Approval, Deepens AI-Driven Healthcare Research

Written by Customer Service on . Posted in Public Companies.

SHANGHAI, Sept. 03, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its technology team will collaborate on a National Natural Science Foundation of China (NSFC) project led by Sun Yat-sen University professor Liang Jianping, the company’s second NSFC-backed research partnership.

The study will examine the influence of human-AI collaboration models on consumer adoption. Fangzhou, the project’s sole corporate partner, will focus on the “AI + chronic disease management”, and work closely with the research team to examine how human–AI collaboration affects consumer adoption of healthcare products and services, while providing support on real-world data collection and model optimization. The project aims to enrich academic understanding in the areas of AI and cognitive science, while also accelerating the broader application of AI in healthcare.

Fangzhou previously contributed to a NSFC project on AI supervision and online consumer behavior in 2024, led by professor Wang Haizhong of Sun Yat-sen University. The two projects underscore Fangzhou’s role in advancing industry-academia collaboration and highlight its commitment to enhancing technical expertise and strengthening AI innovation in healthcare.

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, “Our continued participation in NSFC projects shows that Fangzhou is not only driving commercial success through AI-driven healthcare, but also contributing to China’s broader innovation agenda.”

China has elevated artificial intelligence to a strategic national priority, with the State Council recently issuing guidelines on advancing the “AI+” initiative across six key fields, including healthcare. The NSFC approvals align with this agenda by addressing consumer adoption of AI-enabled products and services.

Fangzhou has invested heavily in research talent and AI innovation. The “H2H Smart Healthcare Ecosystem,” developed by Fangzhou’s technology team, was recognized among Guangzhou’s outstanding “AI+” solutions in 2024. The Company has also developed a comprehensive talent development system focused on building a cross-disciplinary team that combines academic knowledge with industry expertise to enable both professional growth and meaningful contributions to society.

Fangzhou will continue to strengthen participation in national research initiatives and build integrated industry–academia–research innovation platforms, with the goal of translating cutting-edge academic achievements into public healthcare services and contributing to the “Healthy China 2030” goals.

About NSFC Major Research Program
The National Natural Science Foundation’s Major Research Program is the most prestigious and well-funded initiative of its kind, designed to address national strategic needs and scientific frontiers by pooling top resources to boost China’s original research capacity and support economic and social development.

About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.